IONS Price Prediction Next Week
Analysis and Insights
News Sentiment and Insider Activity:
Recent insider activity for Ionis Pharmaceuticals (IONS) shows significant selling. Patrick R. O'Neil, EVP CLO & General Counsel, sold 1,207 shares, representing 2.1% of his holdings. Over the past six months, there have been 30 insider trades, predominantly sales, indicating mixed sentiment among insiders. Institutional investors are also divided, with 170 increasing their positions and 210 reducing theirs.
Technical Indicators:
The stock is currently trading at $32.5, with a Fibonacci pivot point at $32.91. Key resistance levels are at $34.45 and $35.39, while support levels are at $31.38 and $30.44. The RSI_14 is at 56.28, indicating a neutral position, while the MACD is slightly bullish with a value of 0.17.
Valuation Analysis:
IONS has a mixed valuation profile. The stock is trading below its average analyst price target of $62, suggesting potential upside. However, the recent decline of nearly 10% year-to-date and insider selling activity raises caution.
Conclusion:
Based on the technical indicators and news sentiment, the stock is expected to face selling pressure in the next trading week. The price is likely to drop to the lower support level of $31.50.
Recommendation: Sell IONS at the current price of $32.5, with a target price of $31.50.
IONS Similar Chart Price Prediction
The price of IONS is predicted to go up 11.76%, based on the high correlation periods with DKNG. The similarity of these two price pattern on the periods is 92.27%.
IONS
DKNG
Up: 11.76%Similarity: 92.27%
IONS Revenue Forecast
IONS EPS Forecast
IONS FAQs
What is IONS revenue forecast for next quarter？
What is IONS eps forecast for next quarter？
IONS VS S&P500
Ionis' antisense technology and intellectual property estate have allowed the firm to create an entirely new class of therapeutics for difficult-to-treat diseases.
Antisense therapeutics have the potential to gain access to well-studied targets in the cell that are currently deemed
IONS Analyst's Forecast
David Lebowitz
Citigroup
Strong Buy
2025-02-20
Price Target
$67 → $64
Upside
+98.02%
Citi analyst David Lebowitz lowered the firm's price target on Ionis Pharmaceuticals to $64 from $67 and keeps a Buy rating on the shares. The company reported fiscal 2024 earnings, delivering a solid sales beat, mainly driven by Spinraza royalties and better than expected research and development revenue with due to milestone payments realized, the analyst tells investors in a research note. The firm says Wainua's launch remains on track in its first year of launch. Citi sees a "catalyst rich" 2025 for Ionis.
Kostas Biliouris
BMO Capital
Hold
2025-02-20
Price Target
$60 → $45
Upside
+39.23%
Allison Bratzel
Piper Sandler
Buy
2024-11-14
Price Target
$65 → $62
Upside
+80.55%
